Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-436 · 1 trial · 1 indication
Hormones in blood, urine and saliva samples
ABT-436 drug levels in plasma
Blood pressure, pulse
Hematology, chemistry, urinalysis
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-436 | DRUG | QD Days 1-7 |
| Matching Placebo | DRUG | QD Days 1-7 |
Inclusion Criteria 1\. Age between 18 to 55 years, inclusive. 2. Body Mass Index is 20 to 35 kg/m2, inclusive. 3. A primary Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of major depressive disorder. 4\. Mild-to-moderate depressive symp...
Top 20 of 29 competitors
ABT-436 is an investigational small molecule being studied for the treatment of Major Depressive Disorder. It is being developed by AbbVie Inc. and is currently in Phase 1 clinical development. The drug is not approved and remains under investigation for this psychiatric condition.
ABT-436 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is an investigational small molecule in Phase 1 clinical development for Major Depressive Disorder.
ABT-436 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is being studied for Major Depressive Disorder.
ABT-436 has one completed clinical trial, NCT01380704, titled "Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder." This Phase 1 trial enrolled 51 participants and was a randomized, double-blind, placebo-controlled study.
No, ABT-436 is not FDA approved. It is an investigational drug in Phase 1 clinical development for Major Depressive Disorder. The drug is still being studied and has not been approved for any use.